{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-26-005292","form_type":"8-K","ticker":"CMPX","cik":"0001738021","company_name":"Compass Therapeutics, Inc.","filed_at":"2026-08-06T11:30:20+00:00","discovered_at":"2026-08-06T11:35:00.319643+00:00","generated_at":"2026-08-06T11:35:52.163555+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Compass Therapeutics Q2 net loss $25.2M; tovecimig ORR improves to 18.0% with p=0.0228","bullets":["Net loss of $25.2M ($0.13/sh) vs $19.9M ($0.14/sh) in Q2 2025; R&D spend rose 19% to $19.6M.","Cash and marketable securities $180M as of June 30, 2026; runway into 2028.","Tovecimig Phase 2/3 ORR improved to 18.0% (20/111) with p=0.0228 vs paclitaxel 5.3%.","FDA feedback on tovecimig data expected Q3 2026; BLA submission planned later this year.","CTX-8371 cohort expansions enrolling; CTX-10726 Phase 1 dosed; CTX-471 Phase 2 starts Q3."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-26-005292","json":"https://secwatch.observer/filing/0001171843-26-005292.json","markdown":"https://secwatch.observer/filing/0001171843-26-005292.md","text":"https://secwatch.observer/filing/0001171843-26-005292.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1738021/000117184326005292/0001171843-26-005292-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1738021/000117184326005292/f8k_080526.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T11:35:52.163555+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}